A Multi-Center Open-Label Phase I/2 Study of BGB324 in Combination With Erlotinib in Patients With Stage IIIb or Stage IV Non-Small Cell Lung Cancer

Trial Profile

A Multi-Center Open-Label Phase I/2 Study of BGB324 in Combination With Erlotinib in Patients With Stage IIIb or Stage IV Non-Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs BGB 324 (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors BerGenBio
  • Most Recent Events

    • 17 Mar 2017 Planned End Date changed from 1 Dec 2016 to 1 Jul 2018.
    • 17 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 02 Dec 2016 Results of phamacokinetics of BGB-324 plus erlotinib (n=8) presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top